RP Management LLC-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:RP Management LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013291
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
RP Management LLC (RP Management) is a life sciences financing company which offers biopharmaceutical products. Its products portfolio includes rituxan, atripla, thalomid, myozyme, lexiscan, januvia, onglyza, lyrica, prezista, letairis, rotateq, cubicin, savella, neupogen, and others. The company also provides remicade, humira, galvus, nesina, tradjenta, viviant, cimzia, mircera, tecfidera, imbruvica, Xtandi and priligy. RP Management has interests in approved and late stage development bio-pharmaceutical products. It offers its approved products in the therapeutic areas of rheumatoid arthritis (RA), Crohn’s disease, diabetes, chronic kidney disease, HIV/AIDS and others. The company operates through research institutions, inventors, biotechnology and pharmaceutical companies. RP Management is headquartered in New York, the US.

RP Management LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
RP Management LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
RP Management LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
RP Management LLC, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 10
Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 12
Royalty Pharma Acquires Royalties on Cystic Fibrosis Treatments from Cystic Fibrosis Foundation Therapeutics for USD3.3 Billion 14
Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 16
Royalty Pharma Acquires Additional Stake In Tecfidera, Oral Multiple Sclerosis Drug, For US$510 Million 17
Royalty Pharma Acquires Ibrutinib Royalty Rights From Quest Diagnostics For US$485 Million 18
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For US$25 Million 19
Royalty Pharma Acquires BG-12 And Fumaderm From Fumapharm For US$761 Million 21
Prosidion Completes Sale Of Dipeptidyl Peptidase IV Patent Estate And Associated Royalty Interest To Royalty Pharma 22
Royalty Pharma Acquires Royalties Of Lexiscan And Cubicin 24
Venture Financing 25
Avillion Secures Funds from Royalty Pharma 25
Private Equity 26
Aisling Capital And Clarus Ventures Acquire 20% Of Royalty Interest In Ibrutinib From Royalty Pharma 26
RP Management LLC – Key Competitors 27
RP Management LLC – Key Employees 28
RP Management LLC – Locations And Subsidiaries 29
Head Office 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
RP Management LLC, Pharmaceuticals & Healthcare, Key Facts 2
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
RP Management LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
RP Management LLC, Deals By Therapy Area, 2011 to YTD 2017 8
RP Management LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 10
Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 12
Royalty Pharma Acquires Royalties on Cystic Fibrosis Treatments from Cystic Fibrosis Foundation Therapeutics for USD3.3 Billion 14
Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 16
Royalty Pharma Acquires Additional Stake In Tecfidera, Oral Multiple Sclerosis Drug, For US$510 Million 17
Royalty Pharma Acquires Ibrutinib Royalty Rights From Quest Diagnostics For US$485 Million 18
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For US$25 Million 19
Royalty Pharma Acquires BG-12 And Fumaderm From Fumapharm For US$761 Million 21
Prosidion Completes Sale Of Dipeptidyl Peptidase IV Patent Estate And Associated Royalty Interest To Royalty Pharma 22
Royalty Pharma Acquires Royalties Of Lexiscan And Cubicin 24
Avillion Secures Funds from Royalty Pharma 25
Aisling Capital And Clarus Ventures Acquire 20% Of Royalty Interest In Ibrutinib From Royalty Pharma 26
RP Management LLC, Key Competitors 27
RP Management LLC, Key Employees 28

★海外企業調査レポート[RP Management LLC-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sakai Chemical Industry Co Ltd (4078):企業の財務・戦略的SWOT分析
    Sakai Chemical Industry Co Ltd (4078) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Amplia Therapeutics Ltd (ATX):製薬・医療:M&Aディール及び事業提携情報
    Summary Amplia Therapeutics Ltd (Amplia Therapeutics), formerly Innate Therapeutics Ltd, is a pharmaceutical company with focus on the development of focal adhesion kinase (FAK) inhibitors for the treatment of cancer and fibrosis. Its lead drug candidate, AMP945, is a small molecule targeting focal …
  • Tamedia AG:企業のM&A・事業提携・投資動向
    Tamedia AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tamedia AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Amatsigroup SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Amatsigroup SAS (Amatsigroup) is a contract development manufacturing organization that offers human and veterinary pharmaceutical development through preclinical and clinical phases. The organization provides services such as bioservices, clinical trial supply, formulation development and m …
  • AVX Corp (AVX):企業の財務・戦略的SWOT分析
    AVX Corp (AVX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Umeme Limited (UMEME):企業の財務・戦略的SWOT分析
    Umeme Limited (UMEME) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Voyager Therapeutics Inc (VYGR):製薬・医療:M&Aディール及び事業提携情報
    Summary Voyager Therapeutics Inc (Voyager) is a clinical-stage gene therapy company that develops treatments for patients suffering from severe neurological diseases. The company provides treatment for adeno-associated virus gene therapy field by selecting, designing and manufacturing vectors. Its c …
  • Exxon Mobil Corp (XOM):石油・ガス:M&Aディール及び事業提携情報
    Summary Exxon Mobil Corp (ExxonMobil) is an integrated oil and gas company that explores for and produces crude oil and natural gas; manufactures petroleum products; transports and sells crude oil and petroleum products; and markets natural gas and natural gas liquids. It is a major manufacturer and …
  • Black River Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Black River Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • EQT Corporation (EQT):石油・ガス:M&Aディール及び事業提携情報
    Summary EQT Corp (EQT) is an integrated oil and gas company. It operates production fields in Marcellus, Upper Devonian, Ohio Utica and other plays in Appalachian Basin. The company produces and markets natural gas, natural gas liquids (NGL), ethane and crude oil. EQT provides gathering, transmissio …
  • Barry Callebaut AG:企業のM&A・事業提携・投資動向
    Barry Callebaut AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Barry Callebaut AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Great-West Life & Annuity Insurance Co:企業の戦略的SWOT分析
    Great-West Life & Annuity Insurance Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • Citrix Systems Inc (CTXS):企業の財務・戦略的SWOT分析
    Citrix Systems Inc (CTXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Sanmina Corporation (SANM):企業の財務・戦略的SWOT分析
    Sanmina Corporation (SANM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Alon USA Energy Inc (ALJ)-石油・ガス分野:企業M&A・提携分析
    Summary Alon USA Energy Inc (Alon USA), a subsdiary of Delek US Holdings, Inc., is a refiner and marketer of petroleum products. The products offered by the company include various grades of gasoline, diesel fuel, jet fuel, petrochemicals, petrochemical feedstocks, asphalt, and other petroleum-based …
  • PHOENIX Group:企業の戦略・SWOT・財務分析
    PHOENIX Group - Strategy, SWOT and Corporate Finance Report Summary PHOENIX Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • First Solar Inc (FSLR)-エネルギー分野:企業M&A・提携分析
    Summary First Solar, Inc. (First Solar) is a provider of photovoltaic (PV) solar energy solutions. It designs, manufactures and sells PV solar modules with an advanced thin-film semiconductor technology; and also develops, designs, constructs and sells PV solar power systems. The company uses its Cd …
  • Coro Mining Corp:企業の戦略・SWOT・財務情報
    Coro Mining Corp - Strategy, SWOT and Corporate Finance Report Summary Coro Mining Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Integrated DNA Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary Integrated DNA Technologies Inc (IDT) is a biotechnology company that develops diagnostic test products. The company’s products include DNA and RNA synthesis, genotyping, modifications, nextgen sequencing, gene silencing, synthesis genes, and purifications, among others. It offers services s …
  • Polynt SpA:企業の戦略的SWOT分析
    Polynt SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆